Purification and biodistribution of extracellular vesicles by Nordin, Joel Z.
DEPARTMENT OF LABORATORY MEDICINE 
Karolinska Institutet, Stockholm, Sweden 
PURIFICATION AND BIODISTRIBUTION 
OF EXTRACELLULAR VESICLES 
 
Joel Z. Nordin 
 
Stockholm 2017 
 
 All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by E-Print AB 2017 
© Joel Z. Nordin, 2017 
ISBN 978-91-7676-572-2 
Purification and Biodistribution of Extracellular Vesicles 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
By 
Joel Z. Nordin 
Principal Supervisor: 
Assistant Professor Samir EL Andaloussi 
Karolinska Institutet 
Department of Laboratory Medicine 
Clinical Research Center 
 
Co-supervisor(s): 
Professor C.I. Edvard Smith 
Karolinska Institutet 
Department of Laboratory Medicine 
Clinical Research Center 
 
PhD Oscar Simonson 
Karolinska Institutet  
Department of Molecular Medicine and Surgery 
Thoracic Surgery 
 
PhD Imre Mäger 
University of Oxford 
Department of Physiology, Anatomy and Genetics 
 
Opponent: 
Professor Mattias Belting 
Lund University 
Oncology and Pathology 
Kamprad Lab 
 
Examination Board: 
Associate Professor Jorge Ruas 
Karolinska Institutet 
Department of Physiology and Pharmacology 
Molecular and Cellular Exercise Physiology 
 
Professor Matti Sällberg  
Karolinska Institutet 
Department of Laboratory Medicine  
Division of Clinical Microbiology 
 
Professor Einar Hallberg 
Stockholm University 
Department of Neurochemistry 
 
 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For my wonderful wife 
 
  
ABSTRACT 
Extracellular vesicles (EVs) are nano-sized vesicles that contain bioactive lipids, RNAs and 
proteins, which can be transferred to recipient cells. EVs are important for physiological as 
well as pathological processes, such as coagulation and immune homeostasis, aiding cancer 
metastasis and spread of infectious diseases. Owing to their relatively small size the 
purification of EVs is a challenge, hence we have established and optimised workflows 
consisting of ultrafiltration with subsequent size exclusion liquid chromatography (UF-
LC)(Paper I) and bind-elute combined with size exclusion (BE-SEC) columns (Paper III) for 
EV purification. 
 
UF-LC allowed for purification of biophysically intact EVs with better yield and purity 
compared to ultracentrifugation (UC), which is the gold standard purification method in the 
field. The biodistribution of UF-LC EVs was different compared to vesicles isolated using 
UC, despite having highly similar protein composition according to proteomics analysis. We 
found that UF-LC vesicles accumulated less in lung, possibly owing to their higher integrity. 
Indeed, fluorescence correlation spectroscopy and transmission electron microscopy 
indicated that the high gravitational forces in UC lead to aggregation and disruption of the 
vesicles. The BE-SEC method is a similar method to UF-LC, however protein impurities less 
than 700 kDa in size are bound in the interior of the beads, thus improving simple size-based 
exclusion.  The BE-SEC method is scalable, produces samples with better purity than UC, 
displaying yields exceeding 70% and demonstrates a good reproducibility between samples. 
Moreover, vesicles purified by BE-SEC display the same EV surface markers as UC purified 
EVs, and CD63-eGFP positive vesicles are taken up in recipient cells to the same extent. In 
summary, the BE-SEC method is a reproducible and fast alternative to UF-LC for large 
media volumes.  
 
Reliable purification methods are important for the implementation of therapeutically active 
EVs, however knowledge regarding their eventual organotropism and biodistribution is 
equally important. Thus, in article II we evaluated the biodistribution of EVs specifically 
labeled with a near-infrared dye. The main sites of accumulation of exogenously injected EVs 
were liver, spleen and lungs. Biodistribution profile of EVs depended strongly on injection 
route, and to certain extent, on EV cell type source, as dendritic cell derived EVs exhibited a 
more pronounced uptake in spleen compared to the other cell sources tested. We further 
showed that small alterations of EV surface proteins could significantly affect biodistribution 
as well, since EVs equipped with a brain targeting peptide on their surface increased the 
uptake of targeted EVs in brain. This study highlights that the biodistribution of EVs follows 
other nano-sized particles with uptake mainly in liver. Administration route, cell source and a 
targeting peptide influence the distribution, however the overall distribution is unaltered with 
the highest signal originating from liver. 
 
To summarise, this thesis has resulted in improvements of the EV field by systematically 
enhancing EV isolation workflows to achieve greater sample purity and at the same time 
preserving EV biophysical characteristics. Furthermore, it has laid groundwork for studying 
in vivo effects of exogenous vesicles. Both these aspects are particularly important for 
understanding EV biology more clearly and with increased detail.    
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1 INTRODUCTION 
1.1 BRIEF HISTORY OF THE EV FIELD 
The field of extracellular vesicles (EVs) goes back as far as to 1946, when it was discovered 
that high-speed centrifugation of plasma prolonged the clotting time of the supernatant. When 
the pellet was re-introduced to the supernatant, the clotting time was normalised (1), thus, 
suggesting that cell-free plasma contains a “clotting factor” larger than most proteins. This 
“clotting factor” was determined to be small vesicles by electron microscopy in 1967 and 
they were referred to as ”thrombocyte dust” (2). In the following years, several vesicle-
related articles were published, in other biological systems; these included reports regarding 
vesicles involved in bone calcification (3), particles in fetal bovine serum (4), cellular 
fragments from cancer cells (5, 6), vesicles from rectal adenoma microvillus (7) and vesicles 
in seminal fluid (8). In 1983, two articles indicated that EVs had a real biological significance 
when two independent groups demonstrated that EVs were responsible for the shedding of 
the transferrin receptor in maturing reticulocytes as well as proving that the vesicles 
originated from multivesicular bodies (MVBs) (9, 10). In the 1990s, the field of EVs 
advanced further when it was discovered that EVs play a role in immune regulation and could 
elicit a T-cell response (11). However, it was not until 15 years later that the field gained 
increasing attention when three different groups showed that EVs carry ribonucleic acids 
(RNA) and proteins and that these biological cargoes could be transferred to recipient cells in 
various model systems (12-14). Today, EVs are recognised as important intercellular 
messengers in both physiology and pathology (15). The field has expanded rapidly the last 
decade, which is evident by the exponentially growing number of publications annually on 
the NCBI Pubmed website (Fig. 1).  
 
Figure 1. Total number of 
publications retrieved on 
PubMed.org (as of 12th of 
July 2016) with the search 
terms “exosomes”, “micro-
vesicle” and “extracellular 
vesicle” combined, for the 
time period 1990-2015. 
 
1.2 CLASSIFICATION OF EVS 
The nomenclature in the EV field has been under constant debate. EVs have been named in 
innumerable ways during the maturation of the field. Previously, it was common practise to 
name vesicles based on their originating cell type, such as prostasome (8) (prostate cell EVs), 
dexasome (16) (dendritic cell (DC) EVs), matrix vesicles (17) (cartilage and bone EVs) and 
synaptic vesicles (18) (neuronal EVs). However, others have classified EVs based on their 
biogenesis and origin within the cell into three groups (19); exosomes, microvesicles (MVs) 
(also referred to as shedding vesicles, shedding microvesicles, or microparticles) and 
apoptotic bodies (also named apoptotic blebs, or apoptotic vesicles). The main characteristics 
for each group are described in Table 1. However, the discussion regarding the classification 
is still ongoing where researchers have advocated the inclusion of more sub-groupings such 
as ectosomes, membrane particles and exosome-like vesicles (20). However, any such 
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classification is likely an oversimplification as recent evidence clearly suggest high 
heterogeneity even within one vesicle type (21). 
 
Vesicle Type  Size Density (g/mL)  
Morphology 
(in TEM)  Origin 
Markers 
(enriched) 
Exosomes 40-120 nm 
1.13–1.19 
(22)  
Cup-shaped 
(22) Endosomes 
Tetraspanins, 
PDCD6IP, 
MFGE8 etc.* 
Microvesicles 50-1000 nm 
1.03-1.08 
(23)  
Cup-shaped 
(23) 
Plasma 
membrane 
Integrins, CD40 
ligand* 
Apoptotic 
bodies 
500-2000 
nm 
1.16–1.28 
(24) 
Heterogeneous 
(25) 
Plasma 
membrane, 
endoplasmic 
reticulum 
Phosphatidylserine, 
DNA and 
histones* 
Table 1. Characteristics of exosomes, microvesicles and apoptotic bodies. * Not specific for the 
particular vesicle type. g/mL: gram/millilitre, TEM: Transmission electron microscopy, PDCD6IP: 
Programmed cell death 6 interacting protein, MFGE8: Milk fat globule-EGF factor 8, 
DNA:  Deoxyribonucleic acid.   
Exosomes are generally 40-120 nanometres (nm) in diameter, derived from the late 
endosomal pathway within the cytoplasm and are the most well-characterised of the three 
subtypes (15). MVs bud directly from the plasma membrane and are 50-1000 nm in size (15) 
whereas apoptotic bodies are released from apoptotic cells and are more heterogeneous in 
size distribution (15).  Recently, there is increasing number of studies that suggest 
subpopulations of vesicles with different biological properties and phenotypes within each of 
these subgroups (21), further adding to the complexity of vesicle research. In this thesis, the 
term EV will be used to describe all cell-derived vesicles in general, with the exception of 
apoptotic bodies. In certain sections and depending on the context, the other two vesicle 
subgroups (exosomes and MVs) may be specifically defined. 
 
1.3 METHODS FOR EV CHARACTERISATION 
As can be seen from Table 1, vesicles can be classified based on their size, morphology, 
density and protein composition. To date however, there is still no exclusive marker for 
differentiating between exosomes or MVs, even though they have different biogenesis 
pathways (26, 27). Our current methods applicable for cellular work are limited in 
determining the exact vesicle composition within a biological sample, which is likely to be 
highly heterogeneous and stochastic to a certain extent, given the thousands of individual 
proteins detected in an EV sample and the limited EV surface area and volume.  
 
1.3.1 Size characterisation 
One important issue that restricts classification of EVs based on their physicochemical 
parameters is that these nano-sized vesicles are below the detection threshold for normal light 
microscopies (28), thus more specialised alternatives, such as super resolution microscopy, 
transmission electron microscopy (TEM) (11), atomic force microscopy (AFM) (29) or 
similar apparatuses are required. Although modern versions of flow cytometers can now 
detect vesicles down to around 150 nm in diameter, the vast majority of exosomes is smaller 
and therefore excluded (30). New imaging flow cytometers can hopefully detect sub-100 nm 
vesicles, however the technique needs to be further investigated before any clear conclusion 
can be made (personal communication with Dr. A. Görgens). Nanoparticle tracking analysis 
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(NTA) and tunable resistive pulse sensing (TRPS), are examples of newer developments 
tailored for nanoparticle detection, and can be used to assess global particle size distribution 
and concentration in a sample (31, 32), where the size distribution of EV samples often 
resembles a Gaussian profile. Unfortunately, both techniques have a common flaw where 
EVs, protein complexes and/or lipid particles may all mistakenly be interpreted as being 
vesicles. Additionally, operators may manually set thresholds and post-acquisition settings as 
desired and subsequently affect the reproducibility and reliability of NTA results across 
research groups. Thus, these technologies in their current stage should not be used for 
absolute quantitation, but rather as relative measurements in a given experimental setting or 
for describing EV batch-to-batch variability. 
 
1.3.2 Protein evaluation 
To assess the protein composition of EVs, western blot (WB), antibody coated beads for flow 
cytometry as well as mass spectrometry-based proteomics are commonly used (33, 34). 
However, these techniques measure the protein composition of the whole sample and not 
single vesicles. Furthermore, depending on the pre-processing procedure, it is hard to be 
certain whether the identified protein is indeed originating from the EVs or from co-
precipitating protein complexes.  To further study the protein composition, immuno-EM can 
be utilised, which can visualise proteins on the EV surface by immuno-gold secondary 
antibody staining. Fluorescence correlation spectroscopy (FCS) and similar specialised 
equipment can also be utilised to analyse the EVs on a single vesicle level. The downside 
with FCS is that it can only analyse fluorescently labelled EVs, hence either a dye or a 
genetically engineered construct has to be introduced, which limits the analysis to a single or 
only a handful of proteins, similarly to the immune-EM based technologies.  
 
1.3.3 EV density 
Another EV characteristic is its buoyant density that can be measured by density gradient 
centrifugation, using e.g. sucrose or Optiprep™ gradients (20). However, EV density 
measurements are complicated because spin time and loading principle can significantly 
affect the measurement. Additionally, the sucrose gradient is of a hyperosmolar nature (35), 
which can further influence the results by changing water content of vesicles due to osmotic 
pressure. Current evidence nevertheless suggests that EVs can be purified from contaminants 
based on their differential density and that the density of EV subtypes can be different too 
(21), which is important for certain applications. 
 
1.3.4 Evaluation of RNA content 
The deoxyribonucleic acid (DNA) and RNA content of the vesicles is another commonly 
investigated parameter. However extracellular RNA does not only exist in EVs, it can also be 
found as free RNA and bound to proteins or lipoprotein particles (36-38), hence it is 
important to ensure that the purified RNA actually stems from EVs before any analysis is 
undertaken.  Thereafter the RNA content can be analysed with several different methods such 
as qualitative polymerase chain reaction (qPCR), digital PCR, northern blotting, next 
generation sequencing, or simply by fluorescent RNA specific dyes. Depending on the 
method chosen the quality of the obtained data and detection sensitivity can differ. 
Additionally, depending on the extraction method, certain RNA species can be purified from 
EV samples more efficiently than others, possibly introducing bias to RNA analysis and 
posing challenges for data normalization (39). Therefore, similarly to the analysis of EV 
proteins, it is often preferred to analyse changes of a given RNA species within EVs at 
different conditions rather than comparing absolute RNA copy numbers which is more 
sensitive to sample processing biases.  
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1.3.5 Pre-analytical considerations 
Characterisation of EVs in biofluids is even more complicated than in cell culture supernatant 
because there are additional aspects to consider. All the characterisation methods described 
above are additionally influenced by pre-analytical methods, such as venepuncture 
techniques, buffers and anticoagulants used when extracting EVs from plasma or serum, and 
specifics related to biofluid type (e.g. urine, breast milk or saliva). These are similar issues to 
the cell culture where culturing conditions can significantly affect the characteristics of 
isolated EVs (29, 40).  
 
The existing challenges in EV characterisation, as described above, clearly emphasise that in 
order to understand the composition of EVs as artefact-free as possible, it is critical to use 
sufficiently reliable purification methods in the initial sample-processing step. This is also 
recognised by the International Society for Extracellular Vesicles (ISEV) who released a 
statement addressing the minimal characterisation requirements for EV research. ISEV highly 
recommends the use of several different techniques when characterising vesicles, since there 
is no single method that can reliably characterise any given vesicle sample (41). The field, 
nevertheless, has advanced considerably regarding the methods available for the 
characterisation of vesicles, however, it remains extremely difficult to examine vesicles on a 
single vesicle level and it is still unclear how storage conditions and the use of different 
buffers may affect the biophysical and biological properties of vesicles. In the coming years, 
the field will hopefully come to a consensus on the fundamentals of EV research such as 
buffers, storage conditions and more optimisation on current purification methods. 
 
1.4 EV PURIFICATION METHODS 
The purification of EVs has always been a great challenge due to their small size, 
biochemical properties and particularly the complexity of the surrounding fluid. Importantly, 
one needs to pay attention to the selected method for EV purification as it can significantly 
affect the downstream biological results. Whether it is biological fluids or cell culture 
supernatants, one needs to be aware that these are highly heterogeneous fluids containing 
proteins, non-exosomal RNA, dead cells and cell debris as well as lipoprotein particles, and 
possibly other additives in addition to EVs. Blood/plasma/serum is particularly difficult to 
study due to the high viscosity, high abundance of ‘sticky’ proteins, such as albumin, and 
lipoprotein particles and certain protein multimers, such as von Willebrand factor, which is in 
the same size range as EVs (29).  
1.4.1 Ultracentrifugation 
The current gold standard for EV purification is differential centrifugation for the 
sedimentation of vesicles in solution (42). As the high-speed centrifugal forces can pellet 
dense and large particles, a series of lower-speed centrifugation steps with increasing 
speed/centrifugal force are undertaken to initially separate vesicles of different 
sizes/densities. Pelleting efficiency is determined by several factors including, size, density 
and shape of the vesicle, temperature, viscosity and volume of the medium, and whether a 
fixed or swing-out rotor is used (43). The low speed spins normally include a first 300-500g 
spin to get rid of cells and large cell debris, followed by a 1500-2000g spin to get rid of 
smaller cell debris. After the 2000g spin the medium can either be filtered through a 0.2 µm 
filter or spun at 10 000-20 000g to separate out vesicles larger than 100-200 nm in size 
(usually referred to as MVs). The last step is the ultracentrifugation (UC) spin at 100 000-200 
000g to pellet vesicles under 100-200 nm (usually referred to as exosomes). The latter step 
can be repeated as a washing step to achieve higher EV purity (42, 44).  
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Recently, some apprehension has emerged concerning the purity, yield, aggregation, 
intactness and functionality of the vesicles after UC purification (45-48). UC has been shown 
to pellet EVs as well as contaminating proteins and low-density lipoprotein particles. 
Furthermore, aggregates can be present that reduce the therapeutic effectiveness of the 
vesicles or be misleading when studying the active component of the preparation (45, 48, 49). 
Adding a sucrose gradient purification step reduces protein contamination considerably (50), 
however the sample remains contaminated by high density lipoprotein particles present and 
the vesicles are not as functional after sucrose gradient purification (51, 52). It is also 
problematic to scale up the UC process, since most UC rotors are limited to handle up to 400 
mL solution in one run (45). Finally, the technique is highly operator dependent.  
1.4.2 Alternative purification methods 
Consequently, many alternative purification methods have emerged, such as commercially 
available precipitation and immune capture based kits (53), microfluidic devices (MFDs) (54-
58), specific ligands/peptides for exosome binding and purification(59, 60), asymmetrical-
flow field-flow fractionation (A4F) (61, 62), precipitation methods that have even been used 
in the clinic and ultrafiltration techniques (63) with or without subsequent size exclusion 
chromatography (SEC) or ionic exchange chromatography (64-67). Table 2 compares the 
characteristics of three selected purification techniques commonly used in the EV field today.  
 
Potential 
associated issues 
Purification method 
Ultracentrifugation Density gradient centrifugation 
Size exclusion 
chromatography 
High viscosity and 
hyperosmolarity No Yes/No* No 
Recovery Operator dependent** Operator dependent** 80% (66) 
Loss of biological 
activity Yes Yes No 
Cause protein 
aggregation Yes No No 
Cause vesicle 
aggregation Yes  No No 
Contaminating 
proteins and 
lipoproteins 
Yes Less Less 
Time for isolation Around 180 min 6-72 hours 30-60 min 
Table 2. Characteristics for the three main EV purification methods. *High viscosity and 
hyperosmolar media when sucrose is used, however Optiprep™ is isotonic in nature, but still has high 
viscosity. **Operator dependent and the reported recovery yield is typically low. 
 
SEC has been shown to purify EVs devoid of 95% of the high density lipoprotein particles 
and removes 99% of all proteins, however one report showed co-purification of low density 
lipoprotein particles and EVs (48, 66). In the protein purification field, SEC is a well-
established technique with many applications. The technique uses columns containing a 
porous gel-matrix with defined pore sizes and was developed in 1955 (68-70). Briefly, SEC 
works by trapping small molecules within the pores and allows for larger molecules to 
bypass, as they cannot enter the pores. Therefore molecules are separated based on their size 
(i.e. size exclusion), where the largest molecules in a sample elute first and smaller molecules 
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travel a longer distance through the pores of the column matrix, thus eluting later. To date, 
there are several different gel matrix materials and a range of pore sizes available for tailoring 
to the specific sample of interest. For EV purification relatively large pore sizes have been 
used (66), with one report showing the application of SEC columns for fractionation of 
differently-sized EV subpopulations (21). One major advantage with SEC is that the purity of 
EVs from both cell supernatants and biological fluids equals that of density gradient 
centrifugation. Furthermore, EV recovery rates are consistent up to 80% and EV functionality 
is maintained after purification (64, 71-74). Back in the 1980s, SEC was initially used for 
characterisation of EVs rather than purification (10), but nowadays there are even 
commercially available specific EV purification SEC columns which are used by several 
hundred labs world-wide (51).  
 
Another purification method that separates vesicles based on size is A4F, which isolates 
particles via their diffusion properties and has been utilised to separate vesicles with 10 nm 
accuracy (61, 75), however it requires extensive optimisation and specialised equipment.  
 
In a clinical setting, ultrafiltration followed by UC on a sucrose cushion as well as 
polyethylene glycol (PEG)-precipitation have been used (76-82), however the PEG-
precipitation technique is rather poorly characterised. EVs purified with both methods were 
well tolerated by patients. Apart from PEG there are several other commercially available 
precipitation kits, such as ExoQuickTM from System Biosciences and Total Exosome 
IsolationTM from ThermoFisher Scientific, however the exact composition of the chemicals 
used to precipitate the EVs are not revealed by the manufacturers (49). Recently numerous 
other similar kits have been released. Importantly, these kits enrich EVs, however the process 
cannot be regarded as purification, since other protein aggregates and contaminants may also 
be precipitated (49).  
 
MFDs have rendered considerable attention the last couple of years as the amount of starting 
material required for MFDs is commonly very low (<500 µl) and ideal for high-throughput 
screening of rare samples (83). MFDs can be organised into three categories based on their 
mode of action; 1) trapping EVs using immune-affinity, 2) sieving and 3) trapping exosomes 
on porous structures, whereas the most characterised type so far is the first category. In 
addition, one could develop customised MFDs containing functionalised surfaces with 
antibodies that can capture the EVs and directly analyse the readout by fluorescence. For 
instance, this technique was used to show that the fluorescence signal was stronger when 
pancreatic cancer patients serum were analysed compared with healthy controls (58). Another 
recent interesting development for MFDs utilises the combination of a functionalised surface 
and the use of surface plasmon resonance to detect binding to a functionalised surface 
through nano-holes (57). In this set-up, several different ligands with different affinity can be 
applied and the amount of target protein can be extrapolated due to the high sensitivity of the 
surface plasmon resonance technique. Hence, the surface protein composition of EVs can be 
determined. In conclusion, the MFDs are mostly developed for diagnostic purposes where 
they benefit from their small sample volumes and relatively low price.  
 
So far there is still no consensus regarding the best purification technique, which further 
demonstrates the difficulties in assessing and comparing the results between different EV 
studies. It appears that the choice of purification method remains currently a compromise 
between purity, scalability and specific application, choice depending strongly on the sample 
type and posed research question. 
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1.5 EV COMPOSITION  
Despite the challenges of EV characterisation, much is known about their overall 
composition. EVs have a lipid bilayer that resembles the plasma membrane, however certain 
lipids are enriched during the biogenesis, such as phosphatidylserine (PS), sphingomyelin and 
cholesterol (84). EVs contain proteins, RNAs (e.g. intact and fragmented messenger RNA 
(mRNA) (12-14), microRNA (miRNA) (85, 86), transfer-RNA- (87) and ribosomal RNA 
(rRNA) fragments (88) as well as long non-coding RNA (89), etc.), bioactive lipids and 
according to some recent reports DNA (11-14, 84, 90, 91). Due to EV biogenesis related 
sorting mechanisms, as more thoroughly described in the next section of this thesis below, a 
range of proteins are found to be enriched in EVs compared to the cell of origin, including 
tetraspanins, such as CD9, CD63, CD81 and CD82, heat shock proteins, programmed cell 
death 6 interacting protein (PDCD6IP) and tumour susceptibility gene 101 protein (TSG101) 
among others (15, 92) (See Figure 2 for a description of the composition of EVs). 
Importantly, these proteins are mostly considered to be enriched in the exosome fraction as 
compared to their parental cells.   
Figure 2. Overview of the content in Extracellular vesicles. Showing double lipid membrane with 
membrane proteins, soluble proteins and RNA loaded inside the vesicle. MHC: Major 
histocompatibility complex, ESCRT: Endosomal sorting complexes required for the transport  
Proteins enriched in the MV fraction are less studied. One report suggests that β1 integrin is 
enriched in most MVs, whereas other highly enriched proteins in MVs appear to be cell-type 
specific (93), however some proteins materialise to have a rather uniform role in MV budding 
and possibly cargo sorting as well, as explained in the next section. Similarly to exosomes, 
also MV related proteins are devoid of proteins that are normally associated with intracellular 
compartments, such as endoplasmic reticulum and mitochondria, and serum proteins are 
normally not found in EVs (94).  
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Interestingly, regardless of the cellular compartment of origin, some cell specific proteins 
found in EVs have been proposed to be utilised as biomarkers for certain diseases, since EV 
composition changes in disease to a certain extent, mimicking changes in the diseased parent 
cell (95). Because membrane proteins in EVs have the same orientation as in the plasma 
membrane, protein-based biomarkers can potentially be analysed using already existing 
antibodies used in flow cytometry. Although there are a few highly enriched proteins, such as 
the tetraspanins, the majority of the proteins found in EVs are most probably stochastically 
sorted into the EVs and contribute to the high heterogeneity within an EV sample and the rich 
proteome of such sample.  
 
The RNA content in EVs is another highly investigated topic, however to date there are no 
specific RNA markers found to be enriched in EVs derived from different cell lines similar to 
the tetrapanins for EVs. However the vast majority of the RNA found in EV samples is below 
700 nucleotides (nt) (96), whereas mRNA length in cells can be up to 12 000 nt. There have 
furthermore been reports suggesting an enrichment of 3`untranslated regions of mRNA 
molecules (96). Commonly no intact rRNA is found in EVs (14), however some studies 
indicate that the majority of the EV RNA is rRNA fragments (88). Interestingly one study 
showed that the number of miRNAs molecules per vesicle is very low with less than one 
copy per vesicle. The most abundant miRNA molecule in a sample was less than one copy 
per 100 EVs (97). On the other hand, certain proteins at least when overexpressed can be as 
many as 40-50 molecules per vesicle according to FCS readings (personal communication G. 
Corso). 
 
EV protein and RNA composition is highly complex and is specifically related to their 
biological activities. It seems that while certain EV cargoes reflect passively the changes of 
their parent cells, the presence of other cargoes depends strongly on the active sorting via 
interactions with the components important in their biogenesis, as explained next.  
 
1.6 EV BIOGENESIS 
The biogenesis differs for exosomes and MVs because of their different origin within the cell. 
As abovementioned, exosomes originate from the endocytic pathway and MVs are derived 
directly from plasma membrane budding (9, 93), however there have been reports about 
exosomes or exosome-like vesicles originating directly from the plasma membrane as well 
(51, 98). See Fig. 3 for a simplified scheme of the biogenesis of exosomes and MVs.  
 
1.6.1 MVB formation and fate 
The first phase in exosome biogenesis is the inward budding of the plasma membrane to 
generate an early endosome. From the early endosome stage the vesicle and the related 
material can take three distinct routes. The vesicle and its components can be recycled back 
to the plasma membrane, soluble intra-vesicle components secreted, and membrane recycled 
to the plasma membrane (99). The early endosome can also mature into a late endosome and 
in the process become an MVB by inward budding of the endosomal membrane that forms 
intraluminal vesicles (ILVs) (100). MVBs are 250-1000 nm in diameter and the ILVs around 
30-100 nm, thus the same size as exosomes (101). While the process of inward budding to 
create ILVs starts in the early endosome (102), it is clearly enhanced in the maturing 
endosome. Later there are two fates of the developed MVBs, either the MVBs are degraded 
by fusing with a lysosome (103) or the MVBs fuse with the plasma membrane and the ILVs 
are released into the extracellular space as exosomes (11). The regulation of MVB fate is not 
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well understood, however it has been proposed that there are two subpopulations of MVBs in 
the same cell, one population destined for the lysosome and one for fusion with the plasma 
membrane. Two morphologically identical MVB populations with high or low cholesterol 
content have been identified, where the cholesterol rich MVB was more readily fusing with 
the plasma membrane as compared to the low cholesterol population that was rather destined 
for degradation (104). Furthermore, lysobisphosphatidic acid has been detected in lysosomal 
destined MVBs, although never in exosomes (105). While compelling evidence supports that 
there are two distinct populations of MVBs, it is however not clear what dictates the 
segregation of the two subtypes.  
 
1.6.2 Protein sorting and loading into ILVs 
The formation of ILVs and subsequent MVBs appears to be governed by several molecular 
mechanisms and the loading is thought to be highly regulated since exosomes have specific 
cargo proteins (15). The most investigated sorting mechanism to date is the endosomal 
sorting complexes required for the transport (ESCRT) pathway. The ESCRT pathway is 
divided into ESCRT complexes 0, I, II, and III. ESCRT-complexes 0, I and II are responsible 
for detecting and sequestering ubiquitinated membrane proteins on the limiting endosomal 
membrane. The role of ESCRT complex III is to take part in the membrane budding and 
scission of ILVs (106, 107). ESCRT-complexes also associate with auxiliary proteins such as 
PDCD6IP and vacuolar protein sorting-associated protein 4 that are involved in sorting of 
cargo into ILVs and disassembly of the ESCRT-III complex respectively.  
  
Figure 3. Schematic depiction over the biogenesis of Exosomes and Microvesicles. Showing 
MVB fate and key regulators of ILV loading and EV release. MVB: multivesicular body, PDCD6IP:  
Programmed cell death 6 interacting protein, ARF6: Adenosine diphosphate-ribosylation factor 6 and 
MV: microvesicle.  
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The ESCRT-machinery is certainly important for the ILV loading of the MVBs directed 
towards degradation, however it is not clear how important the ESCRT-complexes are for the 
sorting of proteins to the ILVs in the MVBs directed for secretion. For example, there are 
several ESCRT subcomponents enriched in EVs, however only a small fraction of membrane 
proteins in EVs are ubiquitinated, unlike that of most cytosolic EV proteins (108, 109). Since 
ESCRT complexes detect and sequester ubiquitinated membrane proteins, most membrane 
proteins in EVs should, according to this hypothesis, be ubiqutinated if the ESCRT pathway 
was important for the loading of these proteins. Nevertheless, certain components of the 
ESCRT-complex have been shown to be particularly important for MVBs destined for 
secretion, such as PDCD6IP, which associates with the transferrin receptor in reticulocytes 
for the sorting of the receptor into exosomes and the subsequent, shedding of the receptor 
during erythrocyte development (110). Furthermore, PDCD6IP was discovered to take part in 
the sorting of syndecans into exosomes through association with syntenin (111). How 
cytosolic proteins are sorted into ILVs still remains relatively elusive, with one report 
suggesting an association with Heat shock cognate protein 70 (112).  
 
Several other ESCRT-independent mechanisms have been found to be important for exosome 
biogenesis and protein sorting into EVs in recent years. For example, cells depleted of four 
subunits of the ESCRT-complex were still able to produce CD63-positive MVBs (113). In 
addition, sphingomyelinase, an enzyme responsible for the production of ceramide, has been 
shown to regulate exosome biogenesis and secretion in an ESCRT-independent manner 
(114). This correlates well with the high amount of ceramide and ceramide derivatives 
reported in exosomes.  
 
Another important feature that could impact the sorting of proteins, for both EV types, is the 
curvature of the lipid membrane. The importance of the curvature for protein and lipid sorting 
has been studied both in artificial as well as eukaryotic membranes and it has been recognised 
that bacteria can sort proteins to certain micro-domains (115-117). Tetraspanins, have also 
been linked to induce membrane curvature and may contribute to protein sorting mechanisms 
by taking part in this biophysical pathway (118). 
 
Certain tetraspanins, which are highly enriched in exosomes, have also been linked to 
mechanisms directly controlling the sorting of proteins into ILVs (119). Possibly related to 
some functions of tetraspanins, there have also been reports that physical clustering of 
different proteins is important for exosome secretion. For example, the secretion of the 
transferrin receptor, major histocompatibility complex II (MHC-II) molecule and CD43 via 
exosomes increased after antibody crosslinking in reticulocytes, lymphocytes and Jurkat-
cells, respectively (98, 120, 121). Hence, there appears to be both an ESCRT-dependent and 
an ESCRT-independent pathway for the biogenesis and protein sorting into ILVs.  
 
1.6.3 Control of MVB fusion and exosome release 
Several different cellular components are required for the transport of MVBs to the cell 
membrane and the subsequent fusion with the plasma membrane and release of the ILVs. The 
transport of the MVB requires active involvement of the cytoskeleton and its active transport 
mechanisms. The fusion of MVBs with the plasma membrane most likely involves members 
of the SNARE-family, although the exact members of these SNARE components have yet to 
be identified.  Furthermore, several studies suggest small Rab-GTPases as key regulators in 
the secretion of exosomes as models with knockdown of Rab11, 27a and 27b or their effector 
proteins result in significantly lower amounts of exosomes released (122, 123).  
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1.6.4 MV biogenesis 
If the biogenesis and sorting mechanisms appear unclear for exosomes, the picture is even 
more ambiguous for MVs. Similarly to exosomes, small GTPases and other cytosolic 
proteins, such as Adenosine diphosphate-ribosylation factor 6 (ARF6) and TSG101, may 
assist the recruitment of other proteins to the plasma membrane and affect the regulation of 
MV budding (44, 124). The biogenesis of MVs has furthermore been shown to be a result of 
phospholipid redistribution in the plasma membrane and cytoskeleton contractions. The 
phospholipid content in the plasma membrane is not homogenous and forms microdomains 
together with proteins. An increase of phosphatidylserine in the outer-membrane 
leaflet induces MV formation and contractions in the cytoskeleton completes the process 
(125).  To summarize, the biogenesis and protein loading of MVs is not fully understood and 
requires more research.  
 
1.6.5 RNA sorting and loading 
While more information is available regarding protein loading, the sorting of RNA-species 
into EVs remains unclear. In certain cell lines, “zip-code” sequences have been identified in 
EVs (126). However to my knowledge, there is still no ubiquitous RNA sequence that can be 
found in EVs from across all cell types. For small RNA species, some have suggested that the 
presence of RNA-binding proteins may aid their enrichment in EVs. For example, Melo et al 
showed that breast cancer EVs were loaded with miRNAs associated with the RNA-induced 
silencing complex (RISC) and these EVs had the capacity to process precursor miRNAs into 
mature miRNAs independent of their cellular origin (127). This process may be dependent on 
activation status of a particular RISC component protein, as phosphorylated argonaute 2 
inhibited miRNA secretion via EVs (128). Sumoylated hnRNPA2B1, another RNA-binding 
protein, can control the loading of specific miRNAs containing the sequence ‘GGAG’ into 
EVs (129). Furthermore Y-box protein 1 has been implicated in the loading of miRNAs into 
EVs, in cells as well as in a cell free reaction (130). From the data to date, the loading of both 
proteins and RNAs into EVs appears to be tightly regulated by the parental cell and that 
multiple mechanisms can be active simultaneously. However, the exact mechanisms for the 
sorting of both RNAs and proteins and whether these pathways are consistent across cell 
types remain to be elucidated. 
 
In summary, the biogenesis of EVs is a complex process that requires several different 
cellular components. The sorting of proteins into EVs can be dependent on the ESCRT 
machinery as well as through ESCRT-independent mechanisms. The biogenesis is not fully 
investigated and especially MV biogenesis needs further clarification to fully unravel the 
mechanisms that govern EV generation. EV biogenesis is further important for the 
understanding of EV interaction with the surroundings that will be discussed in the next 
chapter.   
 
1.7 EV INTERACTIONS IN VITRO AND IN VIVO 
1.7.1 Effects on recipient cells and uptake mechanisms 
EVs can be seen as advanced signalosomes that can affect recipient cells in a number of 
ways. Surface proteins on EVs, such as receptors and ligands can in their own right prompt 
downstream signalling cascades in cells residing within the vicinity of these EVs. 
Alternatively, after EV internalisation, intra-vesicle proteins can interact with intracellular 
receptors. Another mechanism how the EVs can influence recipient cells is by transferring 
functional receptors onto recipient cells, such as C-C chemokine receptor 5 (CCR5) and 
epidermal growth factor receptor (EGFR) vIII and thereby changing the signalling capability 
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of the cell (131, 132). Furthermore, the RNA content of EVs plays an important role after 
uptake to induce changes in the cellular gene expression profile. The first articles showing 
RNA transfer between cells demonstrated that mRNA can be transferred to and translated by 
recipient cells into functional proteins (12-14). Similarly, there are many later studies 
showing that miRNAs from EVs can induce wide alterations in the epigenetic and protein 
expression profile of cells (85, 133). However, the degree of influence the mRNA and 
miRNA content has on the behaviour and proteome of recipient cells is variable and unclear.  
 
Since many of the actions of EVs on recipient cells described above require EV 
internalisation, the uptake mechanisms of EVs have been a rapidly expanding field.  
Generally, the uptake of EVs appears to be mostly by endocytosis, with some reports on 
pinocytosis by certain cell types (134, 135). A recently published study revealed with elegant 
microscopy techniques that EVs are taken up as single vesicles and that before internalisation 
they ‘surf’ on filopodia. The uptake appeared to be highly effective and a fast phenomenon 
that resembled the way viruses are taken up by recipient cells (136). The uptake can 
furthermore be mediated by Heparan sulfate proteoglycans (HSPG), which has been reported 
to be important for the uptake of cancer cell derived EVs. Cells with low amounts of 
proteoglycans were shown to take up 2.5 fold less EVs compared to wild type cells and the 
uptake was reduced by 50% when HSPGs were enzymatically depleted (137). Furthermore, 
several groups have demonstrated that heparin blocks EV uptake in several cell lines by 50-
80% (59, 137, 138). 
 
Another school of thought governs the possibility of membrane fusion at conditions where 
the cell and EV membrane have the same fluidity. In this instance, the microenvironment 
would play an important role as both membranes appear to have similar fluidity at slightly 
acidic conditions around pH 5 (139), which would enhance the probability of fusion (140). 
This mechanism is thought to be viable for example in tumours where the pH is generally 
lower. It should also be noted that the pH in MVBs is around 5 and that ILVs have been 
shown to back fuse with the MVB limiting membrane (141), thus supporting membrane 
fusion of EVs.   
 
Currently gathered information suggests that similarly to the diverse range of EV-associated 
bioactive molecules and effects, also the interaction mechanisms with their target cells can be 
very varied. This may again reflect the highly heterogeneous nature of secreted vesicles 
whose functions can depend on specific conditions. 
 
1.7.2 Influence of EV surface proteins on biodistribution  
Most studies regarding biomolecular effect mechanisms of EVs have been highly informative 
but have been performed in vitro. However, to understand EV effects in vivo this knowledge 
is insufficient because it does not fully reveal what defines their site of action in an organism. 
In order to understand the latter, it is important to study how EV surface proteins affect their 
biodistribution profile. This is related both to the EV clearance from blood and the 
subsequent distribution in the extracellular matrix, which could be essential to their 
subsequent biological functions. For example, integrins on tumour-derived EVs have been 
shown to influence their biodistribution in mice. Depending on their integrin repertoire, these 
EVs home to different organs and induce a pre-metastatic niche, thus enhancing the spread of 
metastasis (142). Alternatively, other adhesion molecules have been shown to be important 
for the biodistribution. For example, α2,3-linked sialic acids exposed on certain B-cell 
derived EV surfaces can bind to CD169 and regulate the uptake into the spleen and lymph 
nodes (LN) (143). This was further verified when CD169 knock-out mice showed a 
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dysregulated EV trafficking to the LN cortex (143). Another important protein for uptake and 
biodistribution of EVs is Milk fat globule-EGF factor 8 (MFGE8), which binds PS on 
apoptotic cells and EVs. Upon binding to PS, the protein undergoes a conformational change 
(144, 145), which can facilitate the binding of EVs to macrophages expressing αvβ3 and 
αvβ5 integrins and the subsequent phagocytosis of the EVs or apoptotic cells.  
 
Hence, a range of different surface molecules influence the biodistribution of EVs, however 
the uptake in vivo of exogenously administrated EVs appears to be sequestered by immune 
cells in the mononuclear phagocytic system (MPS), as expanded further in the next chapter.  
 
1.7.3 MPS contribute to EV uptake in vivo 
In a bid to further understand the biodistribution of EVs, EVs have been labelled and re-
administered in various mouse models. Interestingly, DiR (1,1'-dioctadecyl-3,3,3',3'-
tetramethylindotricarbocyanine iodide) labelled EVs injected by tail vein injection in 
NOD.CB17-Prkdcscid/J mice, which have a compromised innate immune system as well as 
complement system, had slower EV uptake in the liver and spleen as compared to nude mice, 
which have a compromised adaptive immune system, and Balb/c mice. Therefore, this dataset 
indicated that the complement system as well as the innate immune system may impact on 
the uptake of EVs in the MPS (146). These findings also suggest that EVs are rather similar 
to other lipid nanoparticles which also display complement receptor mediated uptake (147).   
 
Alternatively, PKH26 labelled B16-melanoma derived EVs were taken up by macrophages in 
the liver and spleen however, not in lung, where the EVs appeared to be predominantly taken 
up by endothelial cells (148). Another study found that the clearance from blood of Gaussia 
luciferase labelled EVs was slower in macrophage-depleted mice (148). Moreover, one study 
showed that the uptake of EVs in macrophages was inhibited by dextran sulphate (149), a 
scavenger receptor A inhibitor, which is in accordance with other nano-sized particles that are 
also taken up via scavenger receptors (150). Furthermore, dextran sulphate reduced the 
uptake in liver by 50% when it was co-administrated with the EVs, which subsequently 
enhanced the uptake of EVs in an implanted subcutaneous tumour in the same mice (149).  
 
Hence, compelling evidence support macrophages in the MPS to be important for the uptake 
of EVs intravenously (IV) administered, which may be mediated by MFGE8, scavenger 
receptors, HSPGs and/or complement factors.  
 
1.7.4 EV clearance from blood 
The clearance of EVs from the blood circulation has been shown to be rapid after exogenous 
administration; this can range from as little as 10 to 60 minutes (151-154). Additionally, less 
than 5% of radiolabelled tumour derived EVs injected in nude mice were found in the blood 3 
hours post injection (146). On the other hand, platelet derived EVs were found to have a 
longer half-life in blood of 5.5 hours (155). Besides the origin of EVs, the biophysical 
characteristic of EVs, for example PEGylation, can also increase their half-life in blood. 
Control EVs were cleared from the circulation within 10 minutes, whereas PEGylated EVs 
were still detected 60 minutes after injection (156). Thus, there is a large disparity in the 
reported clearance of EVs, dependent on the type of EVs and model systems used. It is 
proposed that the clearance of EVs from blood is unlikely due to lysis (157), but rather 
dependent on uptake into target organs and most particularly uptake by the MPS as described 
in chapter 1.7.3. To add on, this disparity in the uptake of the nanometre sized particles for 
the different organs may also be linked to the microstructure of the capillaries. Several studies 
have shown that nanoparticles under 100 nm are less prone to be affected by opsonisation and 
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can penetrate the fenestrated endothelium in the liver and can also extravasate in the spleen 
due to the discontinuous endothelium (158-160), thus increasing the uptake of nanoparticles 
in spleen and liver.  
 
In addition to the nature of EVs and model systems, we have found that the biodistribution of 
EVs can also be dependent on the purification technique, since the purification technique can 
influence the integrity and the purity of the vesicles. This data will be further described in 
detail in chapter 4.1. Contrary to our study, another group found that the use of 3 different 
purification methods: UC, Optiprep™-cushion or an Optiprep™-gradient, did not appear to 
influence the clearance of EVs (161). However, the authors found that EVs were recovered to 
a greater extent when the purified EVs were later 0.2 µm filtered after purification of an 
Optiprep™-gradient compared to UC purification (82% versus 50%), again indicating that 
UC causes aggregation of the EVs.  
 
To sum up, many studies have concluded that the half-life of EVs in blood is relatively short, 
however a few studies have demonstrated that specific EVs have longer half-life of up to 
several hours and PEGylation overall prolongs the half-life of EVs. How technical 
differences in purification and/or innate capabilities of the particular EVs investigated may 
affect clearance has yet to be determined.  
 
1.8 BIODISTRIBUTION EVALUATION STRATEGIES 
1.8.1 Chemiluminescense strategies for EV biodistribution 
The biodistribution of EVs has been evaluated using several different labelling strategies, 
including radioactive probes, fluorescent dyes and chimeric biotionylated/strepavidin and 
chemiluminescence proteins (146, 152, 154, 162). For example in the chimeric Gaussia-
luciferase probing method, an EV targeting domain is fused with Gaussia luciferase, allowing 
for the tag to be enriched in EVs. One such EV targeting domain that has been used is the 
C1C2 domain of MFGE8 (148, 152) and another is the membrane part of the platelet-derived 
growth factor (PDGF)-receptor (154, 163). When the PDGF receptor-Gaussia construct was 
used to label HEK293T EVs, the EVs appeared to accumulate mostly in the spleen followed 
by liver, lungs and kidneys 30 minutes after administration. On the other hand, the brain, 
heart and muscle all exhibited a relatively low signal throughout all measured time points 
(154). Interestingly, up to 50% of the signal in the spleen was retained after 360 minutes, as 
compared to the initial 30-minute time point, whereas signals in the lungs and liver fell to 
under 15% and 5% respectively.  
 
Likewise, B16-BL6 derived EVs labelled with the MFGE8 construct presented a similar 
tissue profile, although the most intense signal originated from the liver followed by lungs 
and spleen from the 10 to 60 minute time points, although at the longest time point (4 hours) 
signal was only detected in the lungs during whole animal scans (152). After the organs were 
harvested at 4 hours, luciferase activity was merely detected in lungs and spleen. Importantly, 
in both studies, the authors verified that these signals were resultant of true EVs by using 
sucrose gradient or SEC fractionation to characterise EVs. While the biodistribution is noted 
to be similar between studies utilising Gaussia luciferase to label EVs, there were still some 
important differences between the studies. The discrepancy in distribution between 
HEK293T EVs, that primarily distribute to spleen and liver, and B16-BL6 EVs that more 
readily accumulate in lungs is difficult to interpret. There are a number of reasons that can 
account for these differences; first, these EVs are derived from two different cell lines from 
two different species with varied biological characteristics and second, different EV loading 
proteins were used, which may only label certain subpopulations of EVs. Furthermore, the 
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mice used in these studies were different; HEK293T EVs were injected in immune 
compromised athymic nude mice, whereas the B16-BL6 EVs were injected in immune 
competent BALB/c mice, and different doses were used (100 µg of HEK293T EV- compared 
with 5 µg of B16-BL6 EV-protein).  
 
1.8.2 Fluorescent probes utilised for EV biodistribution 
Apart from chemiluminescence, many different fluorescent dyes and fluorescent probes have 
been utilised to track EVs in animals. To date, for global biodistribution studies in vivo DiR, a 
commercially available lipophilic dye with good in vivo features, such as emission at near 
infra-red wavelengths, has been the most widely used. For example, one study utilised DiR to 
examine the biodistribution of unmodified tumour derived EVs as compared to PC:Chol 
liposomes and liposomes mimicking the lipid composition of EVs (146). In all cases, the 
EVs/liposomes were readily taken up by liver and spleen, with no or weak signal originating 
from orthotropic tumours implanted in the mice. However when the formulations were 
injected intra-tumouraly, the EVs remained associated with the tumour tissue longer than that 
of PC:Chol liposomes. Furthermore, it was shown that the biodistribution in tumour bearing 
mice and non-tumour bearing mice appeared similar, thus, the addition of a tumour did not 
have any impact on the overall biodistribution of exogenously administered EVs or 
liposomes. Another interesting finding of this study was that mice receiving the highest dose 
(400 µg EV protein) had signs of asphyxia and recovered slowly. When the authors tried to 
elucidate the cause for the shortness of breath, these mice did not recover and died 3 minutes 
after the injection. Subsequently, the necropsy found a high accumulation of EVs in the 
lungs, suggesting that the EVs were trapped in the lungs, which caused the symptoms.  
 
DiR has also been used to study the biodistribution of tumour targeted doxorubicin (Dox) 
loaded immature DC EVs (164). These EVs were targeted to tumours by endogenously 
expressing a fusion construct of iRGD with Lamp2b, a reported EV marker, in the parental 
EV producing cells. Strong DiR signal was found in the tumour tissue after 30 minutes and 
peaked around 2 hours after IV injection of iRGD EVs. In contrast, no signal was detected in 
the tumours when non-targeted EVs were injected. When the organs were harvested and 
analysed two hours post injection, the strongest signal was observed in tumour, liver and 
spleen for the targeted EVs whereas non-targeting EVs localised to liver and spleen, but not 
to the tumour. Importantly, administration of these Dox loaded targeted EVs led to the 
reduction in the growth rate of MDA-MB-231 tumours in vivo compared to free Dox and EV 
controls, aptly showing how biodistribution results corresponded with biological readouts. In 
another study, EGFR-targeted EVs for tumour treatment were labelled with DiR and injected 
IV (165). Although the global biodistribution did not appear to change, with the EVs 
predominantly taken up by the liver, EGFR-targeted EVs were found to be taken up in 
tumour tissue 3 times more than control EVs. The EGFR targeted EVs loaded with Let-7a 
miRNA were also shown to supress tumour growth in an orthotropic tumour model.  
 
Other commercial fluorescent dyes have been used to investigate more specific EV 
distribution enquiries. For example, PKH26/67 has been another commonly used dye to track 
tumour EV uptake in organs in several studies and/or track therapeutically active EVs to their 
site of action (142, 165-170). One study showed the uptake of EVs after intranasal delivery 
where they separately studied the delivery of MVs and exosomes. Interestingly, the exosomes 
were found in the brain and intestine, whereas the MVs distributed mostly to the lung. On 
hindsight, free dye also distributed mostly to the lungs (170).  
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In studies using fluorescent dyes, there has yet to be any experiment clearly showing that it is 
only the EVs that are labelled or that all excess dye is completely washed away; which makes 
the results difficult to interpret. Furthermore, when using these unspecific lipid dyes, it is 
unclear which specific group of EVs that are labelled and to what extent the proportion of the 
vesicle pool is actually labelled.  
 
1.8.3 Other biodistribution strategies 
Another biodistribution strategy was employed in an attempt to overcome the latter issue: to 
determine the tissue distribution of EVs Bala et al. used a certain miRNA for biodistribution 
studies. Murine B-cell derived EVs were loaded with miRNA-155 mimics by electroporation 
and injected IV in miRNA-155 knockout mice (171). The distribution of miRNA-155 was 
subsequently analysed by qPCR in perfused organs and found to be highest in liver, adipose 
and lung tissue and lowest in muscle and kidney. The uptake in spleen was not analysed in 
this study. The miRNA was also found to be cleared rapidly from the circulation similar to 
other exogenously injected EVs described earlier.  
 
To sum up, all these described labelling methods most probably show the distribution of EVs. 
Unfortunately, these methods do not indicate whether the EVs are functional in the targeted 
organs they home to. Recently, Cre mRNA has been shown to be loaded into EVs and this 
has been used to demonstrate functional transfer of cancer EVs in vivo (172), however, the 
technique has not yet been utilised to examine the biodistribution of exogenously injected 
EVs. This is difficult because even in in vitro co-culturing systems, this recombinase system 
is highly inefficient with successful recombination in around 1-5% of the recipient cells 
(172).  Nevertheless, the potential of this system was demonstrated in a study in which mice 
expressing Cre recombinase only in the hematopoietic lineages had cells showing 
recombination in the brain. The number of recombined cells in the brain increased after 
systemic inflammation. The authors furthermore found that the EVs from the hematopoietic 
cells contained Cre mRNA that induced recombination when injected in the brain (173).  
 
To conclude, several different strategies to evaluate the biodistribution of EVs have been 
used during the last decade where many studies rely on chemoluminesense and near-infrared 
fluorescent probes. Although these different studies have used different EV sources and 
labelling techniques, the general consensus is that uptake of exogenously IV injected EVs 
follows a similar pattern; with the majority of the EVs rapidly taken up by liver, lung and 
spleen. 
 
1.9 EVS IN HEALTH AND DISEASE 
1.9.1 The good EVs (EVs in physiology) 
As described earlier, EVs contain several key biological components, such as 
receptors/ligands and other membrane and cytosolic proteins, a range of biologically active 
RNAs and bioactive lipids (15). Hence, EVs can influence recipient cells in a number of 
ways depending on their bioactive cargoes and having distinct biological consequences 
during both physiological as well as pathological conditions. This seems to be a general 
organism-wide mechanism, as EVs have been detected in several body fluids including 
blood, urine, cerebrospinal fluid, saliva, bile, breast milk, amniotic fluid and seminal fluid 
(92).  
 
Physiological events that EVs have been implicated in are remarkably diverse, such as blood 
coagulation, both the innate and adaptive immune response, neuronal communication, 
reproduction, embryonic development, tissue repair, bone calcification, liver homeostasis and 
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reticulocyte maturation. It should be noted however that the evidence for the physiological 
importance of EVs in some organ systems is stronger than in others. Examples of well-known 
cases where EVs take part in physiological events are discussed below.  
 
Perhaps the best-described physiological role of EVs are related to the functions of the 
immune system. EVs have been shown to be important players for both immune activation 
and in tolerogenic processes. A key publication in the EV field from Raposo et al. showed 
that B-cells released EVs with peptide loaded MHC-II molecules, which could in turn 
activate T-cells (11). Furthermore, DC derived EVs have been shown to elicit immune 
responses and eradicate tumours in mouse models after systemic injections (174). However, 
immature DC EVs have shown tolerogenic effects in both an arthritis model and in a skin 
graft survival model (175, 176).  Non-immune cell derived EVs seem to affect the immune 
system as well. For example tumour cells secrete EVs that supress inflammatory pathways 
via a number of different mechanisms including enhancement of regulatory T-cell function, 
suppression of natural killer cells as well as CD8+ T-cells (177-179). Additionally, 
mesenchymal stromal cell (MSC) EVs can polarize macrophages to an M2 phenotype further 
extending the immunosuppressive repertoire of EVs (180).  
 
Another organ system where EVs are important is the nervous system where EVs take part in 
processes such as neurite outgrowth, neuronal survival and synaptic plasticity (181-183). EVs 
released from oligodendrocytes as well as Schwann cells have been shown to be protective 
for nerve cells in the peripheral- as well as the central nervous system and partly regulated by 
electrical activity and neurotransmitter release (184).  Stem cell derived EVs have also been 
highlighted as important for the stem cell niche formation as well as in tissue regeneration 
(185, 186). The regenerative capabilities of EVs have been utilised for therapeutic purposes 
discussed in more detail in chapter 1.10.  
 
One area under intense investigation is the role of EVs in the coagulation process. EVs have 
mostly been described as pro-coagulant (1). Mostly larger vesicles have been attributed with 
pro-coagulant characteristics, however studies have shown that smaller EVs can also carry 
tissue factor and hence be pro-coagulant as well (187, 188). Additionally, Scotts syndrome 
which is a bleeding disorder with decreased platelet function has been shown to have a 
reduced phospholipid scramblase activity, which leads to decreased release of pro-coagulant 
vesicles and low pro-thrombinase activity (189).  
 
EVs take part in numerous physiological events from embryonic development to neuronal 
communication and are today seen as important carriers of intercellular messages in order to 
take part in orchestration of these events.  
 
1.9.2 The bad EVs (EVs in pathology) 
Since EVs have such a broad range of effects and are important for many organ systems, it is 
no surprise that they have been linked to several pathological processes, such as cancer, 
spread of infections and prion disease as well as several neurodegenerative diseases when 
their source cells are defective in one way or another. For example, several publications in the 
last couple of years have highlighted the role of EVs in cancer development and especially in 
the metastasis of different cancers.  
 
Research from Professor David Lyden’s group have helped to pinpoint key steps in the 
metastasis of both melanoma and pancreatic cancer where EVs are key players in the initial 
steps of forming the pre-metastatic niche (168, 169). In melanoma, EVs released by 
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melanoma cells polarize bone marrow derived cells to a more pro-metastatic phenotype as 
well as promoting them to migrate to future metastatic organs, such as the lungs, through the 
horizontal transfer of the MET protein. Furthermore, EVs do directly influence the organs 
prone for metastasis of melanomas, for example by enhancing the leakiness of the lung 
vasculature, a phenomena seen early in metastatic melanoma (169). Additionally, pancreas 
adenocarcinoma derived EVs influence Kupffer cells to secrete transforming growth factor-β, 
which induces hepatic stellate cells to produce fibronectin and the resulting fibrotic 
microenvironment increases the recruitment of bone-derived macrophages, which in turn help 
to form a pre-metastatic niche for the pancreas adenocarcinoma cells (168). Moreover, in 
mouse models of both melanoma and pancreas adenocarcinoma, the infusion of cancer cell-
derived EVs increases the metastatic burden significantly even in cancers that have normally 
low rates of metastasis (168, 169).  
 
In addition to the role in metastasis formation, tumour EVs can suppress normal defence 
mechanisms of an organism. Melanoma EVs are commonly drained to LNs where they can 
interact with different immune cells, however there is a subscapular LN layer of macrophages 
that guard the LNs and hinders the melanoma EVs to reach deeper layers of the LNs (163). 
During tumour progression this macrophage layer is disrupted and the EVs can penetrate the 
LNs and interact with other immune cells and prompt a pro-tumour immune response by 
inducing the production of tumour-promoting antibodies.  EVs have also been implicated to 
promote tumour progression in several other ways including, immune escape by altering T-
cells, secretion of metalloproteases which leads to matrix remodelling and directly 
stimulating tumour growth (13, 190, 191). Hence, the interaction between tumour EVs and 
the surrounding cells and tissue is highly complex and macrophages as well as other immune 
cells act in both a tumour suppressive and tumour promoting way after engagement with 
tumour EVs. 
 
In neurodegenerative diseases EVs have been implicated to facilitate the spread of toxic 
proteins. Both α-synuclein and amyloid-β-peptide have been found in EVs and enhance the 
spread of these proteins (192, 193). However, possibly depending on the parent cell or 
specific EV components, in some cases EVs can aid in toxic protein clearance as well (194). 
Certain viruses also take advantage of EVs for their dissemination, such as human 
immunodeficiency virus that utilises the fact that EVs can horizontally transfer the CCR5-
receptor to non-immune cells, which the virus utilises for entry (132).  
 
EV research regarding disease development is very intense and will hopefully in the coming 
years lead to new therapies against cancer and other diseases when our understanding of the 
EVs’ contribution to the disease burden increases. Some success has already been made in 
this field, as summarized in the next section. 
 
1.10 EVS AS THERAPEUTIC MOIETIES 
Given EVs’ functions both in physiological and pathological processes, utilising native or 
modified EVs for therapy has been recognised as a great opportunity. Furthermore, 
modulation of pathogenic EV-related processes by drugs can have significant value for 
therapy as well. The on-going research into therapeutic EVs is focusing on both utilising the 
innate capabilities of EVs as well as to engineer them for specific purposes.  
 
A great example of applicability of native EVs came from the field of cell therapy. MSCs 
have been used to treat several diseases in humans, since they have innate 
immunomodulatory capabilities. However no or very little engraftment of the cells was 
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detected after cell therapy, hence the cells did not replace dying or diseased tissues (195). 
Therefore, researchers started to investigate if paracrine factors could explain the therapeutic 
effect seen after MSC cell infusions. The first articles that reported that MSC derived EVs 
were responsible for the therapeutic effect seen by MSCs emerged in 2009 when the 
therapeutic effect of MSC EVs in animal models of acute kidney injury and acute myocardial 
infarction was shown (196, 197). Since then, the intrinsic immune-modulatory effects of 
MSC EVs have been utilised to treat several other disease animal models including liver 
failure, acute lung injury and ischemic limb disease (198-200). Perhaps the most significant 
example showing the therapeutic effect of EVs is the successful treatment of a human patient 
suffering from Graft versus Host disease using MSC EVs (80).  
 
Another interesting EV source is DCs.  DC EVs primed with cancer antigens are investigated 
as a cancer vaccination strategy and clinical trials have been performed. Early results indicate 
that the treatment is safe, however the therapeutic effect was modest, although all trials had a 
few patients with stabilisation of the disease after therapy (201). The modest effect can be 
due to immune-regulatory mechanisms such as programed death ligand 1 expression and/or 
insufficient stimulation of the T-cells by the EVs. Interestingly, another clinical trial in China 
used EVs derived from ascites fluid from colorectal cancer patients and injected the EVs 
together with granulocyte-macrophage colony-stimulating factor to stimulate a DC response 
against the tumour in vivo (79).  The study found that the treatment was safe and that the 
treatment could elicit tumour specific cytotoxic T-cells. 
 
In line with the benefits of using EVs innate capabilities for therapy, another very intriguing 
approach is to engineer EVs into a potent drug carrier for therapy. This includes strategies 
such as loading them with specific RNAs, proteins and/or to add targeting moieties to their 
surface for specific tissue targeting. Early work showed that cells transfected with a miRNA-
mimic, secreted EVs containing this miRNA-mimic, which could be subsequently transferred 
to recipient cells (202). Later, it was shown that siRNA could be loaded into EVs by 
electroporation (166). The authors also showed that the siRNA loaded EVs could be targeted 
to brain with a brain targeting peptide by transfecting the producing cells with a chimeric 
construct consisting of a brain targeting peptide fused to Lamp2b. After IV infusion of the 
siRNA loaded EVs, the delivered siRNA down regulated genes in the mouse brain in a 
sequence-specific manner. Electroporation as a mean to load EVs has been employed by 
several other labs after the first publication (167, 203-205). However, one caveat is that this 
loading strategy is very inefficient because electroporation leads to precipitation of siRNA 
into crystallised structures that prevent their entry into EVs (206). Nonetheless, there are 
several new publications showing that EVs can still be engineered and exploited for 
therapeutic endeavours. This field of research is still young and many obstacles still remain 
before the technology enters the clinical arena, such as, large scale production and 
purification of modified EVs and specific potency assays that can be employed for quality 
assessments of the EV product. 
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2 AIMS 
The aims of this thesis are related to several crucial issues in the EV research field. Firstly, 
purification methods for isolating pure and intact EVs needed significant improvement. 
Secondly, methods to assess EV biodistribution in an unbiased fashion needed to be 
established. This led to the postulation of individual specific aims of each individual 
publication of this thesis, as stated below. 
2.1 PAPER I - To compare ultrafiltration with subsequent size exclusion liquid chromatography with 
ultracentrifugation for the purification of EVs, especially regarding the yield and 
purity of the EVs.  - To investigate the intactness of the vesicles after purification, since UC purification 
takes place under extreme g-forces. 
2.2 PAPER II - To find a method to explore the biodistribution of EVs without the need for 
genetically engineering the producing cells or selectively label specific subgroups of 
EVs. - Compare the biodistribution of EVs from different cellular sources. - Investigate whether the route of administration or dose influences tissue distribution. - Utilise the method to study how targeting moieties attached on EVs can change the 
biodistribution in mice. 
2.3 PAPER III - To combine size exclusion- with bind elute-liquid chromatography to further stream 
line the workflow during EV purification. - To develope a purification method that would be easy to scale up and at the same time 
keep the vesicles intact and produce a pure sample. 
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3 METHODOLOGY 
3.1 METHODOLOGICAL CONSIDERATIONS 
A full method description is available in the attached articles and manuscript. Here, a brief 
outline of the most important methods will be presented.  
 
3.2 CELL LINES 
The cell lines; NSC-34, a fusion of motor neuron enriched embryonic mouse spinal cord with 
mouse neuroblastoma, Neuro2a (N2a), a mouse neuroblastoma, B16F10, a mouse melanoma, 
HEK293T, human embryonic kidney, C2C12, a mouse muscle, and OLN-93, a rat 
oligodendrocyte, were used. Cells were cultured at 37°C with 5% CO2 in complete media 
comprised of Dulbecco's Modified Eagle Medium (DMEM), supplemented with 10% fetal 
bovine serum (FBS) except for C2C12 which had 20% FBS supplemented, and 
penicillin/streptomycin (P/S, 5000 µg/ml). The conditions used during induced pluripotent 
stem cell and primary cell cultivation is described in the attached articles and collaborators 
cultivated the cells. For EV isolation, the medium was changed 24 hours post seeding to 
either OptiMEM or pre-spun media. Conditioned medium was collected after 48 hours of 
incubation.   
 
3.3 EV PURIFICATION 
EV purification in the three studies has either been by UC, ultrafiltration UF w/o SEC or bind 
elute combined with SEC (BE-SEC).  The most common media to purify vesicles from in 
this thesis were cell supernatants. Both for UC and filtration purification methods the 
conditioned media has been processed before the final purification with a series of 
centrifugations and filtration steps. Firstly the media has been centrifuged at 300g and 
thereafter 1500-2000g to get rid of cell debris. Thereafter a 0.2 µm filtration step has been 
undertaken to separate the larger vesicles from vesicles under 200 nm. Lastly the media has 
been spun at 110 000g for 70 minutes and the pellet re-suspended in PBS and spun again for 
70 minutes in PBS at 110 000g or the media have been ultrafiltrated using commercially 
available 100 kDa spin filters or with tangential flow filtration devices (100 and 300 kDa 
filters used) and the retentate has been further purified by liquid chromatography (LC) on 
Sephacryl columns or BE-SEC columns (CaptoCore 700), all from GE healthcare (Sweden). 
 
3.4 WESTERN BLOT 
WB is used to detected proteins of interest in a sample by applying primary and secondary 
antibodies for the visualisation of the specific protein. In short, the sample was mixed with a 
sample buffer to solubilise and denature the proteins. In the sample buffer sodium dodecyl 
sulfate dissolves hydrophobic regions of the protein as well as breaks non-covalent ionic 
bonds. The β-mercaptoethanol or ditiothreitol is in the sample buffer to break up disulfide 
bonds. Lastly, the sample was heated to completely denature the protein. The proteins were 
then separated by gel electrophoresis and transferred to a nitrocellulose membrane, which 
was blocked by adding blocking buffer. The membrane was then stained with primary and 
secondary antibody and analysed by LI-COR Odyssey CLx infrared imaging system. 
 
3.5 NANOPARTICLE TRACKING ANALYSIS  
NTA was used to measure the particle concentration and size of the EV samples on the 
Nanosight NS500 (Malvern, UK). The NTA measures the particle size based on Brownian 
motion, which is the random movement of particles suspended in solution. The particle size 
can be calculated using the Stokes–Einstein equation. The instrument uses a laser to make 
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particles between 30-1000 nm scatter light that a CCD camera can detect and the computer 
software can then follow the Brownian motion of individual particles and hence calculate the 
size and concentration. The samples analysed were first diluted to achieve a particle count 
between 2 x 108 to 2 x 109 particles per mL. The script control function of the software was 
then used to run the samples and the batch process function used to analyse all samples. The 
setting was maintained throughout one experiment. 
 
3.6 TRANSMISSION ELECTRON MICROSCOPY  
TEM was performed in each study to verify that we indeed had vesicles in our samples that 
resembled EVs. A 2% uranyl acetate solution was used to stain the grids to visualise the 
vesicles.   
 
3.7 LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY (LC-
MS/MS) 
LC-MS/MS was done in collaboration with a group at SciLife lab at Karolinska Institutet in 
Solna. LC-MS/MS is done to elucidate the protein profile of a sample. The sample is 
denatured and cleaved to peptides by trypsin.  The peptides were then analysed by LC-
MS/MS and GO-term enrichment was done by Panther analysis (207).  
 
3.8 FLUORESCENCE CORRELATION SPECTROSCOPY  
FCS was done by collaborators at Novartis in Basel, Switzerland. FCS can measure single 
fluorescent molecules and how they move in solution. Hence the Brownian movement can be 
analysed and the size of the molecule be deducted. Furthermore, the fluorescence intensity of 
each particle can be measured. Here we utilised FCS to measure vesicles in solution to 
determine the concentration, size and fluorescence intensity per particle. From the 
fluorescence intensity, green fluorescent protein (GFP) molecules per particle can be 
calculated. The particles were measured both with and without NP40s treatment. NP40s was 
used to disrupt the particles completely for accurate measurement of “free-GFP” molecules.  
 
3.9 DIR-LABELLING OF EVS 
EVs were generated as normally, however before the first UC spin or UF step, EVs were 
incubated with 1 µM DiR dye. After the incubation, the EVs were purified by UC or UF-LC. 
For certain experiments the DiR labeled EVs were then loaded onto a sucrose gradient to 
measure the density of the labeled vesicles and to make sure that there was no free DiR 
remaining after the washing of the EVs. The reason to use DiR for labeling the EVs is 
because DiR fluoresces near infrared and, hence the penetration in vivo is favourable. DiR 
also has a low background fluorescence when it is free and becomes highly fluorescent when 
bound to a lipid membrane.  
 
3.10 IN VIVO INJECTIONS OF EVS 
EVs were purified by UC or UF-LC and in certain experiments labelled with DiR. The EVs 
were then injected IV in the tail vein, subcutaneously (SC) or intraperitoneally (IP). When 
DiR labelled EVs were used, the biodistribution of EVs was analysed by the In Vivo Imaging 
System (IVIS), where both whole animal scans and scans of harvested organs were 
performed. In the initial dose comparison studies, a range of different EV doses was used. 
Subsequently, we used a fixed dose of 1.0 x 1010 particles/gram of animal body weight.   
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4 RESULTS & DISCUSSION 
4.1 PAPER I 
In this paper we have compared UC with ultrafiltration (UF) with subsequent size exclusion 
LC (UF-LC) for the purification of EVs. This study was undertaken because our lab struggled 
with low yields after UC purification and assumed (as many others in the field) that the high-
speed ultracentrifugation harmed the EVs. In the article, EVs were carefully characterised to 
dissect the advantages and disadvantages with the two purification techniques. We found that 
the UF-LC purified biophysically intact EVs, with high yield and with a proteome that was 
highly similar to UC purified EVs. On the other hand, UC caused EVs to fuse, aggregate 
and/or break, and isolation yields were low and operator dependent.  
 
Firstly, several UC protocols found in the literature were evaluated and we found that it was 
essential to wash the EVs with a second UC round to have as little contaminants as possible 
(results not included in the published article). Hence the UC protocol used for the comparison 
was similar to the one commonly used by the field that was presented by Thery et al in an 
article from 2006 (42).  
 
Thereafter the particle amount was analysed after UC and UF purification respectively and 
according to NTA, UF produced significantly higher amounts of particles. However the 
apparent particle mode size remained the same between the two techniques despite the issues 
with vesicle aggregation and rupture when using UC. Furthermore, WB revealed stronger 
bands for UF samples if the same sample volume was loaded and the bands were of similar 
intensity when matched particle numbers according to NTA were investigated. However, 
when equal amount of protein was loaded onto the gel the UC purified sample displayed 
more intense staining for the same EV markers. Hence protein contamination was higher in 
the UF samples, the main contaminant being albumin as detected by LC-MS/MS.  
 
We ventured on and investigated the biophysical properties of the vesicles by TEM and FCS 
to further study the vesicles after purification. Both TEM and FCS unearthed signs of 
aggregation and breakage of the vesicles after UC purification, whereas the vesicles after UF 
purification appeared to be more intact. In normal light microscopy CD63-eGFP labelled UC 
purified vesicles showed green punctate, whereas UF did not show any punctate at all, only 
diffuse background staining. Furthermore, total internal reflection fluorescence (TIRF) 
microscopy revealed a larger fraction of particles with an area exceeding 2 standard 
deviations of the mean size for UC samples, whereas UF-LC samples displayed a 
homogenous size distribution. Hence both light microscopy and TIRF corroborates the TEM 
and FCS finding that UC causes aggregation and/or vesicle fusion.  
 
UF enriched significantly more particles that were intact compared to UC, however with high 
amounts of protein contaminants. Therefore we sought a method to further purify the vesicles 
with and selected size exclusion LC. After LC, EVs and albumin as well as other protein 
contaminants ended up in two different fractions and the EV samples were purer than UC 
purified samples according to the microgram protein per vesicle ratio (EV purity index) (50). 
Additionally, around 70% of the vesicles were consistently retained after LC purification and 
appeared intact according to TEM. The samples were also analysed by LC-MS/MS and the 
proteome of the EVs after either UC or UF-LC purification was highly similar, which was 
important since it showed that UF-LC purified the same vesicles as UC and the increased 
amounts of particles observed were indeed EVs and not protein contaminants. We also 
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showed that UF-LC could be extended to more heterogeneous/complex starting materials, 
such as stem cell media with maintained better purity as compared to UC. 
 
Importantly, the biodistribution of DiR labelled EVs differed between the two purification 
techniques with UC purified EVs more readily taken up in lung compared to UF-LC samples. 
We speculate that EV accumulation in the lungs was most probably due to aggregation of 
EVs, which could be detrimental for therapeutic applications of such EVs. 
 
In conclusion we showed that UF-LC retained more particles after purification that appeared 
intact compared to UC, which caused aggregation and breakage probably due to the high g-
forces involved in the purification process.  
 
4.2 PAPER II 
The EL Andaloussi group devotes resources to develop EV therapeutics and, thus it is of 
great interest to understand which organs EVs reach upon systemic administration. Therefore, 
the biodistribution of EVs was investigated in Paper II. The DiR labelling technique was 
selected to track exogenously injected EVs in mice and we found that the dose, 
administration route as well as cell source influenced the biodistribution of EVs. 
Furthermore, by including a targeting moiety on the EV surface, uptake into brain was 
increased 2-fold. However, global biodistribution remained the same.  
 
DiR labelling of EVs has been used frequently to track EVs in vivo, however little has been 
done to elucidate if free dye is co-purified with the EVs, which would influence the results 
and possibly lead to misleading conclusions. Hence we first characterised DiR labelled EVs 
after UC purification by floating the EVs on a sucrose gradient, which showed that free dye 
floats on a much lighter density than EV bound DiR and that no or insignificant amounts of 
free dye was co-purified with the labelled EVs, also suggesting sufficient labelling stability in 
a given time frame. The labelled EVs floated on a density similar to the density reported for 
exosomes and co-localised with the EV marker Alix according to WB. The morphology of 
labelled EVs was similar to unlabeled vesicles, appearing cup-shaped in TEM images. After 
the thorough characterisation, we were confident that the dye could be used to track labelled 
EVs in vivo and started with a dose escalation study to analyse how the dose would affect the 
distribution. The dose did affect the distribution to some degree with the highest dose 
accumulating less in the liver, possibly due to the saturation of the MPS. Hence, to avoid 
possible MPS saturating conditions, we chose the intermediate dose (1x1010 particles/gram of 
body weight) for the following experiments. 
  
It is not only the dose that can affect the fluorescence readings, since the dye has a long half-
life, after a certain time the distribution pattern reflects the dye and not EVs. Therefore the 
distribution pattern at different time points (5 minutes to 48 hours post injection) was 
analysed. During the first 24 hours the distribution profile was similar, although at the 5-
minute time point the accumulation in lungs was increased compared to later time points. At 
the 48-hour time point the distribution profile started to deviate from earlier readings with 
increased fluorescence in pancreas and declining values in liver. This could be due to re-
distribution of EVs, a late phase uptake of remaining EVs or most probable an artefact due to 
the long half-life of the dye. Because of the risk of unspecific signals at the 48-hour time 
point, organs were harvested after 24 hours in the subsequent experiments. 
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The most common way to administer EVs according to the literature is by IV injections, 
while other injection routes are less studied, especially in comparative studies. Thus we chose 
to investigate if the administration method influenced the biodistribution of the EVs and 
injected DiR labelled EVs IV, SC and IP.  Both SC and IP administered EVs accumulated 
less in the liver compared to IV injected EVs. Total tissue fluorescence was also weaker for 
SC administrated EVs when analysing individual organs ex vivo, possibly due to the retention 
of the EVs in adipose tissue. These results suggest that different injection locations may be 
utilised for different therapeutic targets, when different pharmacokinetics and/or 
biodistribution are desired.  
 
Next, we examined whether EVs derived from cells originating from different tissues may 
possess organotropic properties. We included EVs from 3 mouse, 1 rat and 2 human cell 
types. The mouse cell sources were C2C12, a muscle cell line, B16F10, a melanoma cell line, 
and lastly primary bone marrow-derived immature DCs. The most significant observed 
difference was that DC derived EVs were distributed more efficiently to the spleen and less to 
the liver compared to the other cell type vesicles. The tissue distribution of EVs from rat and 
human origin was more similar to C2C12 and B16F10 than DC EVs. It is intriguing to 
speculate why DC-derived vesicles show this characteristic distribution. The repertoire of 
surface receptors and integrins has been shown to be important for EV uptake and 
distribution (described in more detail in section 1.7.2) and it is therefore likely that the DC- 
derived EVs possess a unique repertoire of surface molecules that allows the DC-EVs to 
engage more readily with the microenvironment in the spleen. The DCs were also the only 
primary mouse cell, as well as the only cell source of hematopoietic lineage, which may have 
an impact as well.  
 
Lastly, the biodistribution of EVs engineered to be targeted to brain was compared to non-
engineered EVs. Targeted EVs were derived from DCs that had been transfected with a 
chimeric construct of Lamp2b in fusion with the RVG-peptide that is derived from the rabies 
virus and have been shown to promote brain uptake of EVs (see section 1.10). The targeting 
moiety did not change the overall biodistribution as the highest signal was still originating 
from liver, spleen, gastrointestinal tract and lungs, however the accumulation in brain was 2-
fold higher for the targeted EVs compared to non-targeted EVs. This highlights both the high 
sensitivity of the DiR labelling system in detecting subtle differences and that targeting 
moieties do not change the overall biodistribution, but may still allow for more accumulation 
in a targeted organ.  
 
In conclusion we showed that the DiR labelling technique could be applied to EVs for in vivo 
tracking and biodistribution studies. Furthermore, the route of administration, cell source as 
well as targeting moieties influenced the biodistribution, although to different degrees.  
 
4.3 PAPER III 
Paper III is a manuscript that is a follow-up of Paper I although instead of SEC, a 
commercially available BE-SEC column was utilised for EV purification. We show that the 
BE-SEC column can be used to purify vesicles in a scalable, reproducible manner with yields 
of around 70% and still maintains superior purity compared to UC samples. Furthermore, the 
EV surface repertoire and uptake in recipient cells was similar between UC and BE-SEC 
samples.  
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The BE-SEC column has previously been used to purify viruses of similar sizes as EVs and 
hence it is already optimized for similar biological materials (208). The column consists of 
beads that allow material less than 700 kDa into the interior of the bead where it is trapped, 
while larger material is passing through the column without entering the porous resin bead. 
The hypothesis was therefore that the EVs would pass outside the beads and impurities in the 
sample would be confined inside the beads, according to the impurity binding capacity of the 
resin.  
 
Firstly, we showed that the BE-SEC column could purify vesicles from non-concentrated cell 
culture supernatant. NTA, WB and TEM all indicated that the purified particles were indeed 
EVs. According to NTA, the method is reproducible both in terms of the yields achieved and 
vesicle sizes between samples. Hence, the BE-SEC column appears to be an attractive 
technology for EV purification. 
 
Secondly the scalability of the technology was explored. Since the BE-SEC columns have a 
limit for the amount of protein they can bind, larger media volumes were first subjected to a 
diafiltration followed by a concentration step on a tangential flow filtration (TFF) device 
equipped with a 100 kDa molecular weight cut-off filter. The yield after TFF filtration was 
close to 100% and therefore the scalability of the process was further investigated. 
Consequently, increasing media volumes were purified with TFF/BE-SEC and according to 
NTA the increase of purified particles was reproducible and increased with increasing media 
volumes. Furthermore, did WB and TEM reveal vesicle markers and cup shaped particles 
respectively after TFF/BE-SEC purification. Hence, the BE-SEC method combined with a 
TFF step can be considered to be scalable. 
 
The TFF apparatus can be fitted with filters of several different cut-off sizes. In an attempt to 
pre-purify the EV sample during the diafiltration step to a greater extent, we evaluated the 
performance of a TFF filter with a cut off size of 300 kDa. To our surprise the TFF 300 kDa 
filter retained over 95% of the EVs, contrary to the centrifugal filter units with the same 
molecular weight cut-off, which led to a significant loss of vesicles in Paper I experiments 
(unpublished data). Total protein staining and vesicles/µg protein both indicated that the 300 
kDa TFF filter retained less protein impurities compared to the 100 kDa filter, which was 
expected. However the subsequent BE-SEC clean up step achieved practically the same final 
purity using either the 100 or 300 kDa filter cassettes for sample diafiltration, which for both 
was better than for a UC sample.  However, since the EV recovery of the filters is the same, I 
believe the 300 kDa filter ought to be used for EV purification, since it does retain less 
protein contaminations and this can be important when larger media volumes would be used.  
 
One major issue with EV purification is to separate the vesicles from non-vesicular material. 
To analyse BE-SEC performance in the latter, the TFF and TFF/BE-SEC samples were 
separated using an analytical Sepharose 4 Fast Flow SEC column. While the elution 
chromatogram of TFF samples displayed two peaks, the EV and non-vesicular protein and 
RNA peak, the TFF/BE-SEC samples showed only the EV peak. There can still be minor 
amounts of protein impurities left, however the levels were under the detection limit of both 
SEC and total protein staining. In the case of SEC, the protein impurities can also be of the 
same size as the EVs and therefore elute in the same peak, however if the protein aggregates 
would be that large they would probably be visible in the total protein staining, however this 
was not the case.  
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As has been described earlier, the protein surface repertoire of the EVs can be important for 
the biodistribution and therapeutic effect. Therefore, the surface proteins of TFF/BE-SEC and 
UC purified EVs were assessed by flow cytometry beads (34) in order to further verify that 
the TFF/BE-SEC is not biased in purifying only a subclass of vesicles. The bead assay 
revealed the same surface proteins with similar signal intensities for all positive markers for 
both samples. Hence the EVs purified with the two methods appear to carry the same surface 
proteins, which is very encouraging, especially when considering the shorter sample 
processing time of BE-SEC, which is important for achieving higher throughput.  
 
Lastly, the uptake of CD63-eGFP labelled EVs in recipient cells was analysed by flow 
cytometer.  When an equal dose of GFP positive particles was added to recipient cells the 
ΔMFI values were similar for TFF/BE-SEC and UC samples, indicating similar uptake 
characteristics. The uptake was dose dependent for both samples. However, the overlaid 
histograms of the GFP signal revealed a slightly more homogenous cellular uptake 
distribution for the TFF/BE-SEC sample, possibly related to a more homogenous EV sample 
compared to UC. In the article discussed in chapter 4.1 we showed that around 3% of the 
particles detected with TIRF microscopy in UC samples displayed a significantly larger area 
compared to the mean area size of the detected particles, whereas UF-LC purified samples 
were more homogenous with less than 0,5% of larger particles detected. Hence, the more 
heterogeneous histograms for UC purified samples can be due to aggregates in the samples. 
 
In conclusion we show that the BE-SEC column can be utilised for EV purification and 
similarly to the UF-LC method (Paper I), it has unique advantages. It is scalable, reproducible 
with a high yield and better purity than UC purified samples. The BE-SEC columns can in 
the future be used as a last clean up step in the purification process of EVs for animal 
experiments and possibly even clinical samples for diagnostic purposes, however this remains 
to be tested.   
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5 FUTURE PERSPECTIVES 
There are still several issues that are being debated in the EV community, such as a universal 
purification method, sample normalisation strategies, analytical techniques, storage 
conditions, buffers used and EV nomenclature. However since the field is advancing in such 
a rapid pace and new methods for characterisation and detection of EVs are published almost 
on a monthly basis (I have probably missed to mention a few in this thesis), I believe the field 
will homogenise in regard to these aspects.  
 
In the EL Andaloussi group we work on a daily basis to develop EV based therapeutics and 
therefore we have invested many hours on sustainable purification methods, as presented in 
this thesis. Now, when we have established and thoroughly characterised purification 
methods that can be used for large media volumes, the aim is to further develop engineered 
EVs for targeted delivery of therapeutics. The latter requires overcoming many additional 
hurdles, such as short circulation time, possible undesired immune responses and better 
loading strategies for therapeutic molecules. In Paper II we show that EV biodistribution can 
be affected by changing the surface components of the vesicles, hence we are optimistic that 
other modifications may lead to increased EV half-life in blood and targeting to a tissue of 
interest, which is an important prerequisite for many therapeutic applications of EVs as 
envisioned today. EVs have certain features that make them interesting from a drug 
development perspective. They are natural conveyors of intercellular messages, are rapidly 
and effectively taken up by recipient cells, are relatively easy to engineer, they can be loaded 
with both therapeutically active RNAs and proteins and possess desired innate capabilities, 
which can be further enhanced by engineering approaches. However, care must be taken 
because of their general properties, also non-targeted cells are likely to interact with EVs and 
as described in chapter 1.9.2 EVs can aid in disease progression. Consequently, before 
entering clinical trails EVs from the cell source utilised must be carefully characterised and 
investigated in animal models. Furthermore, the loading efficiency of engineered EVs is still 
relatively low, especially for RNA therapeutics and an increase would allow for dose 
reductions and decreased risk of adverse events. Nevertheless, the effects achieved in animal 
models are pronounced after treatment with engineered/loaded EVs, which further indicate 
the great potential of EV therapeutics and EVs ability to convey their cargo to recipient cells.  
 
Another on-going interesting research area is EV subpopulations and EV heterogeneity. 
Today not that much is known regarding subpopulations within the exosome and 
microvesicle field. Recent results indicating that subpopulation of EVs have different effects 
in in vitro models. This is very intriguing and may create further problems regarding both 
purification and classification of EVs in the future. Nevertheless if only a subset of EVs are 
responsible for a therapeutic effect the potential dose may be lower if only the effective 
subset could be purified. For engineered EVs this could be done already today with for 
example affinity chromatography columns.  
 
It is too early to discern if therapeutically active EVs will ever reach the clinic outside clinical 
trails. However if not as a drug, EVs will probably within not such a distant future enter the 
clinic as biomarkers for certain diseases, such as various cancers. EVs utilised as biomarkers 
have not been covered in much detail in this thesis, it is, however an intense research field 
that is more mature than the EV therapy field. Hence, EVs will most probably be used in the 
clinical arena within the coming 10 years, hopefully both as therapeutic agents as well as 
biomarkers for disease.  
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